Invention Grant
- Patent Title: Antisense design
-
Application No.: US15618650Application Date: 2017-06-09
-
Publication No.: US09890383B2Publication Date: 2018-02-13
- Inventor: Signe M. Christensen , Nikolaj Dam Mikkelsen , Miriam Frieden , Henrik Frydenlund Hansen , Troels Koch , Daniel Sejer Pedersen , Christoph Rosenbohm , Charlotte Albaek Thrue , Majken Westergaard
- Applicant: Roche Innovation Center Copenhagen A/S
- Applicant Address: CH Basel
- Assignee: Roche Innovation Center Copenhagen A/S
- Current Assignee: Roche Innovation Center Copenhagen A/S
- Current Assignee Address: CH Basel
- Agency: Fish & Richardson P.C.
- Priority: PAPA2002/01774 20021118; PAPA2003/01540 20031020
- Main IPC: C12N15/11
- IPC: C12N15/11 ; C07H21/02 ; A61K48/00 ; C12N15/113 ; C07H21/04 ; C07H19/06 ; C07H19/16 ; C07H19/04 ; A61K31/7088 ; C07H21/00
Abstract:
A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.
Public/Granted literature
- US20170275628A1 ANTISENSE DESIGN Public/Granted day:2017-09-28
Information query
IPC分类:
